Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.31 USD | -0.87% | -0.72% | -29.81% |
Apr. 15 | Goldman Sachs Cuts Veracyte Price Target to $28 From $32, Maintains Buy Rating | MT |
Feb. 26 | Morgan Stanley Trims Veracyte's Price Target to $21 From $22, Keeps Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.81% | 1.46B | |
-20.45% | 10.67B | |
+43.17% | 3.22B | |
-35.86% | 2.09B | |
-17.21% | 2.04B | |
+17.56% | 1B | |
-4.37% | 734M | |
-37.00% | 391M | |
-46.94% | 379M | |
+13.32% | 343M |
- Stock Market
- Equities
- VCYT Stock
- News Veracyte, Inc.
- Morgan Stanley Adjusts Veracyte's Price Target to $23 from $25, Keeps Underweight Rating